...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Time for a package deal??

I  am wondering if mangement at both Zenith and RVX have finally come to the conclusion that maybe a sale of both entities ,RVX & Zen would be the best solotion to move the science forward . The fact that there is not 1  solid BP Pharma partner on RVX side is the main reason why the science is not moving forward..... Its time IMO to package a deal for both companies so we can see movement of the science at breakthrough speed with the BTD at RVX .  What would the valuation be for both at this point $2 Billion USd $3 Billion 4  Billion USd??  If not now then I think RVX will be spinning there wheels for a long time.  

I would imagine the covid trial would be given FDA emergency authorization by now if a deal with a large BP was done anytime last year.  pathetic at best , come on Don, get over your EGO and move it!!

Share
New Message
Please login to post a reply